The enormous increase in the price of electricity and gas in connection with the energy crisis in the EU was reflected in the increase in the prices of raw materials and the prices of the manufactured products, which led to a decrease of its competitiveness.       
 A positive was the start of the investment to increase the production of Polymyxin B sulfate (the best-selling product of Biotika a.s.).

The company faced the impact of the COVID 19 pandemic (employee outages, raw materials outages, problems with transporting products to risk areas), but managed this crisis situation by implementation of the effective measures.

Ending of contractual manufacturing of L-Cystine for business partner Wacker Chemie AG in end of August 2020

  In 2019 the State Institute for Drug Control issued GMP certificate for the manufacturing of Polymixin B sulfate for our company

By investment to the production line was increased production capacity of the Polymixin B Sulphate by 60%.
In 2018 the  FDA audit was successfully performed for manufacture of Polymyxin B Sulfate  and Phenoxymethylpenicillin potassium with the target to review the observance of GMP requirements in the manufacture of active pharmaceutical ingredients. The State Institute for Drug Control issued of the GMP certificate for the manufacture of Gramicidin S Hydrochloride
 
 

The State Institute for Drug Control issued GMP certificate for the manufacturing of Phenoxymethylpenicillin and L-Cystine for company Biotika.
New version of Certificate of Suitability to the monograph of European Pharmacopoeia for Polymyxin B Sulfate was issued by the European Directorate for Quality of Medicines (EDQM)
In July 2017 Biotika a.s. finished the manufacture of the final dosage  forms and the equipment that were used for this production were sold to AtB Pharma, s.r.o., Sklabinská 28, 036 01 Martin.

In 2015 the State Institute for Drug Control issued GMP certificate for the manufacturing of final dosage forms, Gramicidin S and Polymixin B sulfate for our company.

In 2015 the  FDA audit was successfully performed for manufacture of Polymyxin B Sulfate  and Phenoxymethylpenicillin potassium with the target to review the observance of GMP requirements in the manufacture of active pharmaceutical ingredients.
In 2015 the State Institute for Drug Control issued of the GMP certificate for the manufacture of Gramicidin S Hydrochloride.

In 2014 were performed two certification audits by the SGS certification institution with valid for a period of three years. These audits were focused with the target to review the observance of HACCP requirements (product L-cystine) and FAMI-QS Code (product Aquasta).

Starting of Astaxanthin Production.

Obtain Certificate of Suitability to the Monograph of European Pharmacopoeia for Polymyxin B Sulfate, micronised, the first version, issued by EDQM.

Approval of FDA for Polymyxin B Sulfate, renewed approval for Penicillin V

Biotechnological development of a new amino-acid

Reconstruction of manufacturing line end begining of the contract manufacturing of Gramicidin S for the company Valenta Pharmaceuticals.

Beginning of the Polymyxin B Sulfate production. Extension of production line for the contract manufacuting Wacker Chemie AG. Signing of the contract for manufacture of polypeptide antibiotic with the company Valenta Pharmaceuticals.

End of the first stage of restructuring process in Biotika a.s.

Begining of the contract manufacturing for the company Lonza.
Starting of large reconstruction of waste water treatment plant.
Renewal of FDA Approval for V Penicillin Potassium.

On 1st January 2006 the subsidiary company ČOV a.s. was established, with the main target in the area of waste water treatment and disposal of other waste coming from manufacturing in Biotika a.s.

Beginning of the restructuring process in the company. End of cooperation within join venture Haechst-Biotika, spol. s r.o., Martin. Transfer of business share in this company to the copmany SANITAS AB Latvia.

Joining of the company Middle Europe Investments into Biotika; the daughter company MEI Pharma Slovakia C.V. owns 55 % of Biotika shares.

Manufacture of compact V Penicillin Potassium in new manufacturing premises was started.

Beginning of the contract manufacturing for the company Wacker Chemie AG.
Approval of FDA for V Penicillin Potassium.

Reconstruction of the production plant Pharmacy Martin was realized.

End of cooperation with the company Degussa AG Germany and transfer of business share of Biotika in the company Evonik Fermas to the company Degussa AG.New production of semi-synthetic beta-lactam antibiotics was introduced.

New manufacturing line IMA for the production of dry beta-lactam injection preparations was open.

In 1996 the privatization process was finished. Majority shareholder - company G.V.Pharma, which acquired 42 % of shares. Other majoritywere the Slovak bank VÚB a.s. (17 %) and Moorgate Securities Ltd (7 %). The rest minority shareholders (<5 %), owned together 34 %. First steam-gas cycle/cogeneration unit in the SR was implemented in Biotika a.s.

In the second half of this year the new information system BPCS was implemented; this system is still valid and used.

New plant for downstream processing was open.

On 25^th January 1993 the limited company Evonic Fermas s.r.o. in Slovenská Ľupča was established by the companies Biotika and Degussa AG Germany, with the proportion of business shares 50 % for both founders.
New production of solid beta-lactam preparations was introduced.

Up to 1992 Biotika was a national enterprise as a part of SPOFA concern. Biotika as a joint-stock company was founded in the year 1992, when the privatization process began. On 2^nd March 1992 the limited company Hoechst-Biotika, s.r.o. in Martin was founded by the companies Biotika a.s. and Hoechst Aktiengesellschaft Germany.

Starting the L-Threonine production.

Opening the new built plant for Penicillin production.

Starting the production of Tylozine – veterinary preparation.

Research and development laboratory is transformed into the R&D branch, which was garanted by a status comparable to that of specialized R&D Institutions in the Czechoslovakia.

Starting the L-Lysine production; Biotika was actually the third company in the world, after the USA and Japan, which started to manufacture the L-Lysine by fermentation method.

Starting the production of veterinary injection medicaments.

Starting the production of veterinary injection medicaments.

Traditional substances production was expanded by biofactors manufacturing and production of injections for human use. The manufacturing plant in Martin becomes a part of Biotika.Production of streptomycin and chlortetracycline was started.

Starting the production of V Penicillin.

Biotika established its own laboratory of research and development. Its first result was he shortened procedue for preparing the raw potassium salt of G Penicillin – the initial substance for manufacturing of the final preparations of G Penecillin.

Starting the production of G Penicillin.

Establishment of national enterprise Biotika as a part of SPOFA concern covering all pharmaceutical manufacturing comapanies in the former Czechoslovakia. Original target of national enterprise was the manufacture of Penicillin – the most progressive drug of that time.